The Incidence of Deep Venous Thrombosis in Patients with an Acute Myocardial Infarction Treated with Acenocoumarol or Indobufen

Summary

In a randomized double blind clinical trial, we compared indobufen, an antiplatelet drug, with acenocoumarol for the prevention of deep venous thrombosis (D. V. T.) in patients with acute myocardial infarction. Therapy was started on admission and continued for 10 days. All patients were screened daily with impedance plethysmography (I.P.G.) and 125I-fibrinogen leg scanning. Diagnosis of D.V.T. was made when either one or both tests became positive. 74 patients were randomized to treatment with indobufen (200 mg b.i.d.) and 76 patients to acenocoumarol (controlled by thrombotest). The incidence of venous thrombosis in patients with indobufen was 11% and in those treated with acenocoumarol 9%. Major bleeding was observed in 2 patients treated with acenocoumarol. In the indobufen group, no bleeding complications or other serious side-effects were observed. The majority of patients developed thrombosis after the first week of admission. For patients with and without thrombosis, there was no significant difference between the two treatment groups concerning the age, the coronary prognostic index, the maximum C.P.K. value, mobility, incidence of congestive heart failure and the site or extent of the infarct. In this study no clinical or laboratory (fibrinogen, platelet count and anti-thrombin III) parameter, either alone or in combination, was of predictive value for the development of D.V.T. It can be concluded that indobufen appears to be as good as acenocoumarol for the prevention of D.V.T. in patients with acute myocardial infarction. Because it is safe and easy to administer, indobufen seems to be preferable. Prophylaxis is required for at least 10 days.

Keywords

Deep vein thrombosis - Acute myocardial infarction - Indobufen

• References

• 1 Murray TS, Lorimer AR, Cox FC, Lawrie TDV. Leg vein thrombosis following myocardial infarction. Lancet 1970; 2: 792-793
• 2 Nicolaides AN, Kakkar VV, Renney JTG, Kidner PH, Hutchinson DCS, Clarke MB. Myocardial infarction and deep vein thrombosis. BrMed J 1971; 1: 432-434
• 3 Maurer BJ, Wray R, Shillingford JP. Frequency of venous thrombosis after myocardial infarction. Lancet 1971; 2: 1385-1387
• 4 Pussell BA, Pitney WR. The use of anticoagulants in the prevention of venous thrombosis after myocardial infarction. Med J Aust 1972; 2: 1101-1103
• 5 Handley AJ, Emerson PA, Fleming PR. Heparin in the prevention of deep vein thrombosis after myocardial infarction. Br Med J 1972; 2: 436-438
• 6 Wray R, Maurer B, Shillingford J. Prophylactic anticoagulant therapy in the prevention of calf vein thrombosis after myocardial infarction. N Engl J Med 1973; 288: 815-817
• 7 Simmons AV, Sheppard MA, Cox AF. Deep venous thrombosis after myocardial infarction. Predisposing factors. Br Heart J 1973; 35: 623-625
• 8 Gallus AS, Hirsh J, Tuttle RJ, Trebilcock R, O’Brien SE, Carol JJ, Minden JH, Hudecki SM. Small subcutaneous doses of heparin in prevention of venous thrombosis. N Engl J Med 1973; 288: 545-551
• 9 Warlow C, Beattie AG, Terry G, Ogston D, Kenmure ACF, Douglas AS. A double blind trial of low doses of subcutaneous heparin in the prevention of deep vein thrombosis aftermyocardial infarction. Lancet 1973; 2: 934-936
• 10 Marks P, Emerson PA. Increased incidence of deep vein thrombosis after myocardial infarction in non smokers. Br Med J 1974; 3: 232-234
• 11 Mustard JF. Platelets, drugs and thrombosis. In: Hirsh J, Cade JF, Gallus AS, Schonbaum E. (eds) Platelets, drugs and thrombosis. S. Karger; Basel: 1975: 1-14
• 12 Harris WH, Salzman EW, Athanasoulis CA, Waltman AC, De Sanctis RW. Aspirin prophylaxis of venous thromboembolism after total hip replacement. N Engl J med 1977; 297: 1246-1249
• 13 McKenna R, Galante J, Bachmann F, Wallace DL, Kaushal SP, Meredith P. Prevention of venous thromboembolism after total knee replacement by high dose aspirin or intermittent calf and thigh compression. Br Med J 1980; 280: 514-517
• 14 Tamassia V, Corvi G, Fuccella LM, Moro E, Tosolini G, Tremoli E. Indobufen (K 3920), a new inhibitor of platelet aggregation; effect of food and bioavailability, pharmacokinetic and pharmacodynamic study during repeated oral administration in man. Eur J of Clin Pharmacol 1979; 15: 329-333
• 15 Fuccella LM, Corvi G, Moro E, Pogliani E, Tamassia V, Tosolini G. Pharmacokinetic, bioavailability and pharmacodynamic study of indobufen (K 3920), inhibitor of platelet aggregation, after single administration in man. Eur. J Clin Pharmacol 1979; 15: 323-327
• 16 Owren PA. Thrombotest: a new method for controlling anticoagulant therapy. Lancet 1959; 2: 754-758
• 17 Norris RM, Brandt PWT, Caughey DE, Lee AJ, Scott PJ. A new coronary prognostic index. Lancet 1969; 1: 274-278
• 18 Kakkar VV. Fibrinogen uptake test for detection of deep vein thrombosis – a review of current practice. Semin Nucl Med 1977; 7: 229-244
• 19 Morris GR, Mitchell JRA. Evaluation of 125I-fibrinogen test for venous thrombosis in patients with hip fractures: comparison between isotope scanning and necropsy findings. Br Med J 1977; 1: 264-266
• 20 Hull R, van Aken WG, Hirsh J, Gallus AS, Hoicka G, Turpie AGG, Walker I, Gent M. Impedance plethysmography using the occlusive cuff technique in the diagnosis of venous thrombosis. Circulation 1976; 53: 676-700
• 21 Warlow CP, Terry G. The possible use of 125I-labelled fibrinogen for the detection of mural thrombosis following myocardial infarction. Am Heart J 1974; 88: 315-318
• 22 Abildgaard U, Lie M, Ødegaard OR. Antithrombin (heparin co-factor) assay with new chromogenic substrates (S-2238 and chromozym TH). Thromb Res 1977; 11: 549-553
• 23 Clauss A. Gerinnungsphysiologische Schnellmethode zur Bestimmung des Fibrinogenes. Acta Haematol 1957; 17: 237-246
• 24 Eastham RD. Simple method for separating platelets from red cells before enumeration with an electronic counter. J Clin Path 1965; 18: 248-249
• 25 Loeliger EA. The optimal therapeutic range in oral anticoagulation. History and proposal. Thromb Haemostas 1979; 42: 1141-1152
• 26 Pitney WR, Hickey A, Gopinath A, Dean S. Is the incidence of deep vein thrombosis following myocardial infarction decreasing?. Aust N Z J Med 1980; 10: 167-171
• 27 Cristal N, Stern J, Ronen M, Silverman C, Ho W, Bartov E. Identifying patients at risk for thromboembolism. Use of 125I-fibrinogen in patients with acute myocardial infarction. JAMA 1976; 236: 2755-2757
• 28 Hull R, Hirsh J, Sackett DL, Powers P, Turpie AGG, Walker I, McBride J. The value of adding impedance plethysmography to 125I-fibrinogen leg scanning for the detection of deep vein thrombosis in high risk surgical patients. A comparative study between patients undergoing general surgery and hip surgery. Thromb Res 1979; 15: 227-234
• 29 Selzer A. Use of anticoagulant agents in acute myocardial infarction: statistics or clinical judgment?. Am J Cardiol 1978; 41: 1315-1317